微采样支持治疗药物监测的经济学证据:系统综述
研究提示微采样可能降低TDM成本,但经济学报告质量中等(CHEERS标准50%至71%),且无研究同时考虑成本与临床结局。
要点
- 微采样支持TDM的经济学证据有限,仅3项研究符合纳入标准。
- 一项预测DBS可降低成本达61%,主要与生产力损失相关。
核心结论
- 研究提示微采样有潜力降低TDM成本,但需更多工作评估成本与临床结局并优化物流以支持临床实施。
主要发现
- 共纳入3项研究(包括1项随机对照试验),其中2项报告成人免疫抑制剂TDM的DBS(1项还报告VAMS),1项报告儿科患者免疫抑制剂或唑类抗真菌药TDM的DBS。
- 两项研究报告实施结局(包括样本递送时间),一项报告有效性(包括患者满意度),一项报告临床验证。
- 无研究同时考虑成本与临床结局。
- 一项研究预测DBS可降低成本达61%,主要与生产力损失相关;一项研究报告微采样设备的相对成本。
关键数值与推荐
- 经济学报告质量中等,CHEERS标准符合范围为50%至71%。
局限性
- 纳入研究数量少(仅3项),且无研究同时评估成本与临床结局,经济学报告质量中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Microsampling approaches could potentially streamline therapeutic drug monitoring (TDM) for patients who require monitoring across time and may be cost-saving. The aim of this systematic review was to summarize the available economic evidence on microsampling when used to support TDM. Scopus, PubMed and the NHS Economic Evaluation databases were searched (inception to November 2024) for studies that reported on costs associated with microsampling to support TDM. Two authors reviewed the studies and extracted data. Overall quality of economic analysis was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Three studies (including one randomized control trial) were eligible. Two studies reported on dried blood spots (DBS) to support immunosuppressant TDM in adults, one also reporting on volumetric absorptive microsampling (VAMS). One study reported on DBS to support immunosuppressant or azole antifungal TDM in paediatric patients. Two studies reported on implementation outcomes, including sample delivery time, one on effectiveness, including patient satisfaction, and one on clinical validation. No study considered costs alongside clinical outcomes. One study reported no cost reduction with DBS home-sampling (€688 vs. €676, p = .66), one predicted DBS could reduce costs by up to 61%, largely related to loss of productivity. One study reported relative cost of microsampling equipment. Economic reporting quality was modest (CHEERS criteria range 50% to 71%). Studies suggest the potential of microsampling to reduce TDM costs, but more work is needed to assess cost alongside clinical consequences and to optimize logistics to support implementation of microsampling into clinical workflow.
引用
- Carland JE, Connor D, Starr M, et al. The economic evidence for microsampling to support therapeutic drug monitoring: A systematic review. Br J Clin Pharmacol. 2025. PMID: 41290535. doi:10.1002/bcp.70338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。